

**Drug Usage Assessment for Blood Draw (F29a)**  
**Version: 10/01/05c**

1. Add sentence to initial prompt on form indicating that form does not need to be completed for HIV-negative women. All HIV-positive women, even those not taking ART, should complete the form.
2. Add a new class of antiretroviral drugs called “Integrase Inhibitors.”
3. Add Isentress (raltegravir, MK 0518), drug code 264, to Integrase Inhibitor category. Isentress was approved by the FDA on October 12, 2007.
4. Add Intelence (etravirine, TMC 125), drug code 255, to NNRTI category. Intelence was approved by the FDA on January 18, 2008.
5. Delete Agenerase (amprenavir) from the PI category. This drug has been completely removed from the U.S. market as of October 2007.
6. Delete Hivid (ddC) from the NRTI category. This drug has been discontinued as of December 31, 2006.
7. Delete Fortovase from the PI category. Saquinavir is now sold only in the Invirase formulation.